alendronate has been researched along with Hypercalcemia in 49 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hypercalcemia: Abnormally high level of calcium in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term treatment of cats with ionized hypercalcemia using alendronate has not been evaluated." | 9.20 | Treatment of ionized hypercalcemia in 12 cats (2006-2008) using PO-administered alendronate. ( Braudaway, SR; Chew, DJ; de Brito Galvao, JF; DiBartola, SP; Green, TA; Hardy, BT; Lord, L, 2015) |
| "A randomized, double-blind, dose-ranging study of single-dose intravenous (IV) therapy with alendronate sodium (aminohydroxybutylidene bisphosphonate) was performed in patients with cancer-associated hypercalcemia." | 9.07 | Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. ( Averbuch, SD; Bilezikian, JP; Gertz, BJ; Glusman, J; Nussbaum, SR; Rude, R; Sacco, JF; Stepanavage, M; Stewart, AF; Warrell, RP, 1993) |
| "Describe clinical findings in a cohort of cats with persistent ionized hypercalcemia and evaluate long-term tolerance and efficacy of alendronate in these patients." | 8.12 | Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases. ( Benchekroun, G; Canonne-Guibert, M; Da Riz, F; Desquilbet, L; Kurtz, M; Maire, J; Maurey, C, 2022) |
| "The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia." | 7.78 | Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012) |
| "Cinacalcet is effective in controlling the biochemical abnormalities in patients with primary hyperparathyroidism (PHPT) but it seems to be less effective on bone mineral density (BMD)." | 7.77 | Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. ( Colao, A; Coppola, A; Di Somma, C; Faggiano, A; Gasperi, M; Lombardi, G; Panico, F; Ramundo, V; Savastano, S; Severino, R; Vuolo, L, 2011) |
| " We report here the use of oral alendronate for the treatment of hypercalcemia due to vitamin D intoxication in a 7 month-old infant with nephrocalcinosis." | 7.73 | Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. ( Atabek, ME; Pirgon, O; Sert, A, 2006) |
| "Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve." | 7.70 | Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000) |
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 5.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Long-term treatment of cats with ionized hypercalcemia using alendronate has not been evaluated." | 5.20 | Treatment of ionized hypercalcemia in 12 cats (2006-2008) using PO-administered alendronate. ( Braudaway, SR; Chew, DJ; de Brito Galvao, JF; DiBartola, SP; Green, TA; Hardy, BT; Lord, L, 2015) |
| "A randomized, double-blind, dose-ranging study of single-dose intravenous (IV) therapy with alendronate sodium (aminohydroxybutylidene bisphosphonate) was performed in patients with cancer-associated hypercalcemia." | 5.07 | Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. ( Averbuch, SD; Bilezikian, JP; Gertz, BJ; Glusman, J; Nussbaum, SR; Rude, R; Sacco, JF; Stepanavage, M; Stewart, AF; Warrell, RP, 1993) |
| " Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia." | 4.79 | [Paraneoplastic syndrome]. ( Hara, N; Nakanishi, Y; Takayama, K, 1997) |
| "Describe clinical findings in a cohort of cats with persistent ionized hypercalcemia and evaluate long-term tolerance and efficacy of alendronate in these patients." | 4.12 | Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases. ( Benchekroun, G; Canonne-Guibert, M; Da Riz, F; Desquilbet, L; Kurtz, M; Maire, J; Maurey, C, 2022) |
| "The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia." | 3.78 | Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012) |
| "Cinacalcet is effective in controlling the biochemical abnormalities in patients with primary hyperparathyroidism (PHPT) but it seems to be less effective on bone mineral density (BMD)." | 3.77 | Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. ( Colao, A; Coppola, A; Di Somma, C; Faggiano, A; Gasperi, M; Lombardi, G; Panico, F; Ramundo, V; Savastano, S; Severino, R; Vuolo, L, 2011) |
| "In recent years, alendronate, an oral biphosphonate, has been added to therapy of hypercalcemia secondary to vitamin D intoxication in children." | 3.74 | Intragastric alendronate therapy in two infants with vitamin D intoxication: a new method. ( Caner, I; Doneray, H; Karakelleoglu, C; Ozkan, A; Ozkan, B, 2008) |
| " We report here the use of oral alendronate for the treatment of hypercalcemia due to vitamin D intoxication in a 7 month-old infant with nephrocalcinosis." | 3.73 | Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. ( Atabek, ME; Pirgon, O; Sert, A, 2006) |
| "Alendronate sodium is an aminobiphosphonate, an analog of inorganic pyrophosphate, indicated for the treatment of osteoporosis in post-menopausal women." | 3.72 | Pharmacovigilance study of alendronate in England. ( Biswas, PN; Shakir, SA; Wilton, LV, 2003) |
| "Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve." | 3.70 | Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000) |
| "The inhibitory effect of murine interferon gamma (muIFN gamma) on humoral hypercalcemia in nude mice bearing lower-jaw cancer (LJC-1-JCK), in which parathyroid-hormone(PTH)-related protein is responsible for causing humoral hypercalcemia by activating bone resorption, was examined in comparison with that of a new bisphosphonate, 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (alendronate)." | 3.69 | Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). ( Arita, H; Kakudo, S; Kasai, H; Tohkin, M, 1994) |
| "Primary hyperparathyroidism is a common endocrine disorder that results in elevated levels of parathyroid hormone and subsequent hypercalcaemia." | 2.53 | Primary hyperparathyroidism and the role of the nurse. ( Walker, J, 2016) |
| "They are used in the treatment of Paget's disease of bone, hypercalcaemia and osteolytic bone disease of malignancy, primary and secondary hyperparathyroidism, and in osteoporosis." | 2.41 | Bisphosphonates: an overview with special reference to alendronate. ( Vasikaran, SD, 2001) |
| "Alendronate treatment achieves normocalcemia four times earlier than prednisolone treatment and shortens hospital stay in infants with vitamin D intoxication." | 1.38 | Comparison of oral alendronate versus prednisolone in treatment of infants with vitamin D intoxication. ( Bereket, A; Bozaykut, A; Guran, T; Paketçi, C; Seren, LP; Sezer, RG, 2012) |
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 1.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| "Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa." | 1.31 | Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). ( Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L, 2002) |
| "Alendronate was administered to rats made hypercalcemic by treatment with parathyroid hormone-related peptide (PTHrP)." | 1.30 | Alendronate inhibits osteopontin expression enhanced by parathyroid hormone-related peptide (PTHrP) in the rat kidney. ( Azuma, Y; Fujita, K; Hirota, S; Iguchi, M; Kohri, K; Nomura, S; Ohta, T; Sasaki, S; Yasui, T, 1998) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Hypercalcemia was treated with an investigational aminobisphosphonate." | 1.28 | Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas. ( Hutchison, JS; Kaufman, SD; Mitlak, BH; Nussbaum, SR, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.04) | 18.7374 |
| 1990's | 16 (32.65) | 18.2507 |
| 2000's | 18 (36.73) | 29.6817 |
| 2010's | 12 (24.49) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Widler, L | 1 |
| Jaeggi, KA | 1 |
| Glatt, M | 1 |
| Müller, K | 1 |
| Bachmann, R | 1 |
| Bisping, M | 1 |
| Born, AR | 1 |
| Cortesi, R | 1 |
| Guiglia, G | 1 |
| Jeker, H | 1 |
| Klein, R | 1 |
| Ramseier, U | 1 |
| Schmid, J | 1 |
| Schreiber, G | 1 |
| Seltenmeyer, Y | 1 |
| Green, JR | 1 |
| Kurtz, M | 1 |
| Desquilbet, L | 1 |
| Maire, J | 1 |
| Da Riz, F | 1 |
| Canonne-Guibert, M | 1 |
| Benchekroun, G | 1 |
| Maurey, C | 1 |
| Rajput, S | 1 |
| Dutta, A | 1 |
| Rajender, S | 1 |
| Mithal, A | 1 |
| Chattopadhyay, N | 1 |
| Sahu, A | 1 |
| Hwang, Y | 1 |
| Vilos, C | 1 |
| Lim, JM | 1 |
| Kim, S | 1 |
| Choi, WI | 1 |
| Tae, G | 1 |
| Larson, MJ | 1 |
| Oakes, AB | 1 |
| Epperson, E | 1 |
| Chew, DJ | 3 |
| Hardy, BT | 1 |
| de Brito Galvao, JF | 2 |
| Green, TA | 1 |
| Braudaway, SR | 1 |
| DiBartola, SP | 1 |
| Lord, L | 1 |
| Walker, J | 1 |
| Parker, V | 1 |
| Schenck, PA | 1 |
| Farag, N | 1 |
| Delbanco, T | 1 |
| Strewler, GJ | 1 |
| Kusamori, K | 1 |
| Katsumi, H | 1 |
| Abe, M | 1 |
| Ueda, A | 1 |
| Sakai, R | 1 |
| Hayashi, R | 1 |
| Hirai, Y | 1 |
| Quan, YS | 1 |
| Kamiyama, F | 1 |
| Sakane, T | 1 |
| Yamamoto, A | 1 |
| Whitney, JL | 1 |
| Barrs, VR | 1 |
| Wilkinson, MR | 1 |
| Briscoe, KA | 1 |
| Beatty, JA | 1 |
| Faggiano, A | 1 |
| Di Somma, C | 1 |
| Ramundo, V | 1 |
| Severino, R | 1 |
| Vuolo, L | 1 |
| Coppola, A | 1 |
| Panico, F | 1 |
| Savastano, S | 1 |
| Lombardi, G | 1 |
| Colao, A | 1 |
| Gasperi, M | 1 |
| Bollerslev, J | 1 |
| Marcocci, C | 1 |
| Sosa, M | 1 |
| Nordenström, J | 1 |
| Bouillon, R | 1 |
| Mosekilde, L | 1 |
| Sezer, RG | 1 |
| Guran, T | 1 |
| Paketçi, C | 1 |
| Seren, LP | 1 |
| Bozaykut, A | 1 |
| Bereket, A | 2 |
| Iglesias, P | 1 |
| Castro, JC | 1 |
| Abreu, C | 1 |
| Díez, JJ | 1 |
| Onuchic, L | 1 |
| Ferraz-de-Souza, B | 1 |
| Mendonca, BB | 1 |
| Correa, PH | 1 |
| Martin, RM | 1 |
| Hashida, H | 1 |
| Honda, T | 1 |
| Morimoto, H | 1 |
| Aibara, Y | 1 |
| Matsumoto, Y | 1 |
| Kurita, M | 1 |
| Erdogan, T | 1 |
| Biswas, PN | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Onuma, E | 1 |
| Azuma, Y | 3 |
| Saito, H | 1 |
| Tsunenari, T | 1 |
| Watanabe, T | 1 |
| Hirabayashi, M | 1 |
| Sato, K | 1 |
| Yamada-Okabe, H | 1 |
| Ogata, E | 1 |
| Atabek, ME | 1 |
| Pirgon, O | 1 |
| Sert, A | 1 |
| Orbak, Z | 1 |
| Doneray, H | 2 |
| Keskin, F | 1 |
| Turgut, A | 1 |
| Alp, H | 1 |
| Karakelleoglu, C | 2 |
| Minisola, S | 1 |
| Scillitani, A | 1 |
| Romagnoli, E | 1 |
| Antoniucci, DM | 1 |
| Sellmeyer, DE | 1 |
| Bilezikian, JP | 2 |
| Palermo, L | 1 |
| Ensrud, KE | 1 |
| Greenspan, SL | 1 |
| Black, DM | 1 |
| Letonturier, P | 1 |
| Sugimoto, T | 1 |
| Diskin, CJ | 1 |
| Stokes, TJ | 1 |
| Dansby, LM | 1 |
| Radcliff, L | 1 |
| Carter, TB | 1 |
| Shah, BK | 1 |
| Gowda, S | 1 |
| Prabhu, H | 1 |
| Vieira, J | 1 |
| Mahaseth, HC | 1 |
| Wermers, RA | 1 |
| Recknor, CP | 1 |
| Cosman, F | 1 |
| Xie, L | 1 |
| Glass, EV | 1 |
| Krege, JH | 1 |
| Ozkan, B | 1 |
| Caner, I | 1 |
| Ozkan, A | 1 |
| Tohkin, M | 1 |
| Kakudo, S | 1 |
| Kasai, H | 1 |
| Arita, H | 1 |
| Koyano, H | 1 |
| Schimizu, T | 1 |
| Shishiba, Y | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 1 |
| Ohta, T | 2 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 1 |
| Budayr, AA | 1 |
| Zysset, E | 2 |
| Jenzer, A | 2 |
| Thiébaud, D | 1 |
| Ammann, P | 2 |
| Rizzoli, R | 4 |
| Jaquet-Müller, F | 2 |
| Bonjour, JP | 3 |
| Gertz, B | 1 |
| Burckhardt, P | 2 |
| Rodan, GA | 1 |
| Balena, R | 1 |
| Lin, JH | 1 |
| Chen, IW | 1 |
| deLuna, FA | 1 |
| Hichens, M | 1 |
| Nussbaum, SR | 2 |
| Warrell, RP | 2 |
| Rude, R | 1 |
| Glusman, J | 1 |
| Stewart, AF | 1 |
| Stepanavage, M | 1 |
| Sacco, JF | 1 |
| Averbuch, SD | 1 |
| Gertz, BJ | 2 |
| Body, JJ | 1 |
| Coleman, RE | 1 |
| Piccart, M | 1 |
| Nakanishi, Y | 1 |
| Takayama, K | 1 |
| Hara, N | 1 |
| Greenwald, RA | 1 |
| Stein, B | 1 |
| Miller, F | 1 |
| Yasui, T | 1 |
| Fujita, K | 1 |
| Sasaki, S | 1 |
| Iguchi, M | 1 |
| Hirota, S | 1 |
| Nomura, S | 1 |
| Kohri, K | 1 |
| Sadamori, N | 1 |
| Taguchi, J | 1 |
| Imaizumi, Y | 1 |
| Tsushima, H | 1 |
| Yoshida, S | 1 |
| Hata, T | 1 |
| Soda, H | 1 |
| Tomonaga, M | 1 |
| Ohnishi, T | 1 |
| Takeda, E | 1 |
| Yogita, S | 1 |
| Miyake, H | 1 |
| Kinoshita, T | 1 |
| Terashima, Y | 1 |
| Matsumoto, T | 1 |
| Tashiro, S | 1 |
| Vasikaran, SD | 1 |
| Portmann, L | 1 |
| Pryor-Tillotson, S | 1 |
| Buchs, B | 1 |
| Mitlak, BH | 1 |
| Hutchison, JS | 1 |
| Kaufman, SD | 1 |
| Kozak, S | 1 |
| Trechsel, U | 1 |
| Fleisch, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Post-Cardiac Surgery Vitamin D Deficiency in Children With Congenital Heart Disease: A Pilot Dose Evaluation Randomized Controlled Trial[NCT01838447] | Phase 2 | 46 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis[NCT00005005] | Phase 2 | 238 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| The Denosumab And Teriparatide Administration Study (DATA)[NCT00926380] | Phase 2 | 94 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood 25OHD will be measured to determine vitamin D deficiency, with a concentration below 50 nmol/L used to define deficiency. A PICU admission blood sample could not be obtained for one patient in the Usual Care Group and one patient in the High Dose Group, thus the total number analyzed differs from the full sample size. (NCT01838447)
Timeframe: 1 day (On admission to the pediatric intensive care unit (PICU) following CHD surgery)
| Intervention | nmol/L (Mean) |
|---|---|
| Usual Care Group | 34.8 |
| High Dose Group | 52.0 |
Hypercalcemia will be defined as an ionized calcium level above 1.40 mmol/L; or above 1.45 mmol/L for children under 8 weeks. Hypercalcemia will be evaluated in blood collected immediately before CHD surgery and throughout the post-operative course (measurements are standard of care). (NCT01838447)
Timeframe: Immediately before surgery, on admission to the PICU following CHD surgery, and on post-operative days 1,3,5 & 10
| Intervention | No. participants with hypercalcemia (Number) |
|---|---|
| Usual Care Group | 0 |
| High Dose Group | 0 |
Primarily, post-operative catecholamine requirements during the PICU admission will be evaluated as a dichotomous variable (yes/no). If a difference is noted in the primary analysis, inotrope requirements will be determined using the inotrope score, evaluated as the maximum score and in a time to event approach (off all inotropes, score of zero) (NCT01838447)
Timeframe: At any point between PICU admission and discharge, an average length of 5-7 days and not longer than 60 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care Group | 15 |
| High Dose Group | 11 |
Hypercalciuria will be identified using calcium:creatinine ratios defined using age-specific norms and thresholds. (NCT01838447)
Timeframe: Immediately before surgery, on admission to the PICU following CHD surgery, and on the first post-operative day
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Enrolment | Intra-operative | Post-Operative Day 1 | |
| High Dose Group | 0 | 4 | 1 |
| Usual Care Group | 1 | 3 | 2 |
(NCT00926380)
Timeframe: Baseline and 2 years
| Intervention | percent change (Mean) |
|---|---|
| Denosumab ONLY | 8.3 |
| Teriparatide (Forteo®) ONLY | 9.5 |
| Denosumab and Teriparatide (Forteo®) | 12.9 |
11 reviews available for alendronate and Hypercalcemia
| Article | Year |
|---|---|
Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Deno | 2023 |
Primary hyperparathyroidism and the role of the nurse.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Humans; Hyperca | 2016 |
Update on Feline Ionized Hypercalcemia.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium; Cat Diseases; Cats; Diagnosis, Diff | 2017 |
Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism.
Topics: Alendronate; Animals; Bone Resorption; Evidence-Based Medicine; Humans; Hypercalcemia; Hyperparathyr | 2011 |
Vitamin D intoxication and therapy with alendronate (case report and review of literature).
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Child; Creatinine; Humans; Hypercalcemia; Ma | 2006 |
[Progress in diagnosis and therapy: Hypercalcemia due to primary hyperparathyroidism].
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Calcium; Diagnosis, Differential; Diagnos | 2007 |
Bisphosphonates in the treatment of metabolic bone diseases.
Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Humans; Hyp | 1993 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
[Paraneoplastic syndrome].
Topics: Alendronate; Anticoagulants; Cushing Syndrome; Diagnosis, Differential; Diphosphonates; Disseminated | 1997 |
Bisphosphonates: an overview with special reference to alendronate.
Topics: Alendronate; Bone Density; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Dipho | 2001 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
7 trials available for alendronate and Hypercalcemia
| Article | Year |
|---|---|
Treatment of ionized hypercalcemia in 12 cats (2006-2008) using PO-administered alendronate.
Topics: Administration, Oral; Alendronate; Animals; Calcium; Cat Diseases; Cats; Drug Administration Schedul | 2015 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcium; Drug Combinations; Female; Humans; Hyp | 2008 |
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Diphosphonates; Dose-Response Rel | 1993 |
Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Doub | 1992 |
Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
Topics: Aged; Alendronate; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Dose-Response Relations | 1992 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
32 other studies available for alendronate and Hypercalcemia
| Article | Year |
|---|---|
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques | 2002 |
Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases.
Topics: Alendronate; Animals; Calcium; Cat Diseases; Cats; Cohort Studies; Hypercalcemia; Retrospective Stud | 2022 |
A novel alendronate functionalized nanoprobe for simple colorimetric detection of cancer-associated hypercalcemia.
Topics: Alendronate; Animals; Calcium; Colorimetry; Female; Gold; Hypercalcemia; Metal Nanoparticles; Mice; | 2018 |
Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat.
Topics: Alendronate; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cat Diseases; Cats; Diphos | 2019 |
Update: A 64-year-old woman with primary hyperparathyroidism.
Topics: Adenoma; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Progressio | 2008 |
Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Butylated Hydroxytoluene; Calcium; Female; G | 2010 |
Use of bisphosphonates to treat severe idiopathic hypercalcaemia in a young Ragdoll cat.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cat Diseases; Cats; Diphosphonates; Female; | 2011 |
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cinac | 2011 |
Comparison of oral alendronate versus prednisolone in treatment of infants with vitamin D intoxication.
Topics: Administration, Oral; Alendronate; Anti-Inflammatory Agents; Bone Density Conservation Agents; Drug | 2012 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans | 2012 |
Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Drug Therapy, Combina | 2012 |
[An elderly case suspected of familial hypocalciuric hypercalcemia subsequent to manifestation of hypercalcemia].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium; Female; Humans; Hypercalcemia; Pedigree | 2002 |
Oral bisphosphonate therapy for vitamin D intoxication of the infant.
Topics: Administration, Oral; Alendronate; Bone Diseases; Hand; Humans; Hypercalcemia; Iatrogenic Disease; I | 2003 |
Pharmacovigilance study of alendronate in England.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Angioedema; Cohort Studies; Erythema Multiforme; Family | 2003 |
Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Bone Resorption; Calcitonin; Calcium; Cell Line, Tumor | 2005 |
Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Drug Overdose; Female; Humans; | 2006 |
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type I; Glucocorticoids; Human | 2006 |
[Questions and answers about bisphosphonates].
Topics: Administration, Oral; Age Factors; Alendronate; Bone Density; Bone Density Conservation Agents; Bone | 2007 |
Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin.
Topics: Aged; Alendronate; Calcitonin; Diphosphonates; Female; Humans; Hypercalcemia; Lung Neoplasms | 2007 |
Modern milk alkali syndrome--a preventable serious condition.
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Diuretics; Female; Fluid Therapy; Furosemide | 2007 |
Intragastric alendronate therapy in two infants with vitamin D intoxication: a new method.
Topics: Alendronate; Bone Density Conservation Agents; Drug Overdose; Female; Humans; Hypercalcemia; Infant; | 2008 |
Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK).
Topics: Adult; Alendronate; Animals; Bone Resorption; Calcium; Diphosphonates; Female; Granulocyte Colony-St | 1994 |
The bisphosphonate dilemma.
Topics: Alendronate; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; False Negative Reaction | 1995 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Topics: Alendronate; Calcitriol; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; N | 1994 |
Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
Topics: Alendronate; Animals; Blood Proteins; Calcium; Calcium Radioisotopes; Diphosphonates; Hydrogen-Ion C | 1993 |
Rapid skeletal turnover and hypercalcemia associated with markedly elevated interleukin-6 levels in a young black man.
Topics: Adult; Alendronate; Alkaline Phosphatase; Black People; Bone and Bones; Bone Remodeling; Collagen; C | 1998 |
Alendronate inhibits osteopontin expression enhanced by parathyroid hormone-related peptide (PTHrP) in the rat kidney.
Topics: Alendronate; Animals; Blotting, Northern; Diphosphonates; Gene Expression; Hypercalcemia; Kidney; Ma | 1998 |
Efficacy of bisphosphonate for hypercalcemia in patients with adult T-cell leukemia.
Topics: Adult; Alendronate; Female; Humans; Hypercalcemia; Leukemia, T-Cell; Male; Middle Aged | 1999 |
Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma.
Topics: Aged; Alendronate; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Hypercalcemia; Liver N | 2000 |
Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas.
Topics: Adenoma, Islet Cell; Aged; Alendronate; Cyclic AMP; Diphosphonates; Female; Humans; Hypercalcemia; P | 1991 |
Effect of a single injection of two new bisphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinosarcoma 256/B in thyroparathyroidectomized rats.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Carcinoma 256, Walker; Diphosphonates; Hypercalcemia | 1987 |